Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Vaxcyte (PCVX) has provided an update.
Vaxcyte, Inc. has appointed John P. Furey as a Class II director to its Board, effective July 2, 2024, with his term expiring at the 2025 annual stockholders’ meeting. Recognized as an independent director, Furey will also join the Compensation Committee. He received an $800,000 stock option as part of his initial compensation, with a vesting period over 36 months, and will receive annual equity awards valued at $450,000, plus annual cash retainers totaling $57,500 for his board and committee roles. His compensation aligns with the Company’s non-employee director program, ensuring vested interests in the company’s growth and governance.
Learn more about PCVX stock on TipRanks’ Stock Analysis page.
